Italia markets open in 1 hour 56 minutes

BioInvent International AB (publ) (0H22.L)

LSE - LSE Prezzo differito. Valuta in SEK.
Aggiungi a watchlist
44,540,00 (0,00%)
Alla chiusura: 05:13PM BST

BioInvent International AB (publ)

The Gamma Building
Ideongatan 1
Lund 223 70
Sweden
46 4 62 86 85 50
https://www.bioinvent.com

Settore/i
Settore
Impiegati a tempo pieno111

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Martin Welschof Ph.D.President & CEO5,06MN/D1961
Mr. Stefan Ericsson M.B.A.Chief Financial OfficerN/DN/D1963
Ms. Marie Moores M.Sc., R.G.N.Chief Operating OfficerN/DN/DN/D
Mr. Kristoffer Rudenholm HanssonSenior Vice President of Technical OperationsN/DN/D1974
Mr. Björn FrendéusChief Scientific Officer2,35MN/D1973
Ms. Cecilia HofvanderSenior Director of Investor RelationsN/DN/D1967
Dr. Andres McAllisterChief Medical OfficerN/DN/D1956
Ms. Ingrid TeigeHead of Preclinical ResearchN/DN/DN/D
Ms. Sylvie RyckebuschChief Business OfficerN/DN/DN/D
Dr. Ingunn Munch LindvigSenior Vice President of Regulatory AffairsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.

Governance aziendale

L'ISS Governance QualityScore di BioInvent International AB (publ) al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 3; diritti degli azionisti: 1; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.